Scholarlink

Background <p>ZBED2 is a member of the C2H2-zinc-finger BED-type zinc-finger protein family. However, the clinical significance and potential functions of ZBED2 in various cancers have not been systematically explored.</p> Methods <p>In this article, we comprehensively analyzed multi-omics and bulk sequencing data to explore the characteristics of ZBED2 in pan-cancer and its potential utility in cancer treatment. We investigated the expression pattern, association with prognosis, possible functions, correlation with tumor immunity, tumor-associated mutations, and drug sensitivity of ZBED2.</p> Results <p>ZBED2 was significantly differentially expressed in more than 60% of the cancer types (<i>p</i> &lt; 0.05). High expression of ZBED2 was an independent risk factor for a poor prognosis in many cancer patients (<i>p</i> &lt; 0.05 and Hazard Ratio &gt; 1). ZBED2 functional enrichment analysis revealed that ZBED2 expression was associated with pathways, such as immune and lipid metabolism pathways. ZBED2 expression was positively correlated with a hot immune microenvironment and was significantly correlated with immunotherapy response (<i>p</i> &lt; 0.05). In addition, the overexpression of ZBED2 was negatively correlated with DNA methylation. More importantly, P300-mediated super-enhancer activity drove ZBED2 expression. Finally, we used R software to screen out 16 drugs likely to bind to ZBED2 (correlation coefficients &lt; -0.2 and <i>p</i> &lt; 0.0001) and performed molecular docking, and molecular dynamics simulation for the top six drugs.</p> Conclusions <p>Collectively, by bioinformatics analysis, this study regards ZBED2 as a potential diagnostic, prognostic biomarker for many cancers and a predictive biomarker for immunotherapy, providing new insights for the application of ZBED2 in tumor targeted therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multi-omics and bulk sequencing analyses reveal the roles of prognosis and immune aspects of super-enhancer-induced ZBED2 in pan-cancer

  • 期刊论文

  • 发表日期：

    2025年11月25日

查看全文
  • Jiao Ren,
  • Na Zhang,
  • Luoyu Zhu,
  • Jinglei Zhang,
  • Xiaolin Ma,
  • Xiuxiu Zhang,
  • Jiaqiu Li,
  • Jinwei Cai

摘要

Background

ZBED2 is a member of the C2H2-zinc-finger BED-type zinc-finger protein family. However, the clinical significance and potential functions of ZBED2 in various cancers have not been systematically explored.

Methods

In this article, we comprehensively analyzed multi-omics and bulk sequencing data to explore the characteristics of ZBED2 in pan-cancer and its potential utility in cancer treatment. We investigated the expression pattern, association with prognosis, possible functions, correlation with tumor immunity, tumor-associated mutations, and drug sensitivity of ZBED2.

Results

ZBED2 was significantly differentially expressed in more than 60% of the cancer types (p < 0.05). High expression of ZBED2 was an independent risk factor for a poor prognosis in many cancer patients (p < 0.05 and Hazard Ratio > 1). ZBED2 functional enrichment analysis revealed that ZBED2 expression was associated with pathways, such as immune and lipid metabolism pathways. ZBED2 expression was positively correlated with a hot immune microenvironment and was significantly correlated with immunotherapy response (p < 0.05). In addition, the overexpression of ZBED2 was negatively correlated with DNA methylation. More importantly, P300-mediated super-enhancer activity drove ZBED2 expression. Finally, we used R software to screen out 16 drugs likely to bind to ZBED2 (correlation coefficients < -0.2 and p < 0.0001) and performed molecular docking, and molecular dynamics simulation for the top six drugs.

Conclusions

Collectively, by bioinformatics analysis, this study regards ZBED2 as a potential diagnostic, prognostic biomarker for many cancers and a predictive biomarker for immunotherapy, providing new insights for the application of ZBED2 in tumor targeted therapy.